Skip to main content

Table 2 Multivariable Cox regression associating 17 bile acid levels or ratio of conjugated bile acids to unconjugated bile acids and 5-year overall survival for patients ≥ 55 years old (n = 197) adjusting for age, sex, tumor anatomic location, stage, and chemotherapy use

From: Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

Bile acid/ratio

HR

CI95

P value

CA

0.94

0.37–2.42

0.905

GCA

1.18

0.34–4.06

0.796

DCA

0.84

0.29–2.41

0.742

LCA

1.11

0.48–2.59

0.807

UDCA

1.08

0.41–2.89

0.873

TDCA

1.29

0.33–5.03

0.718

TLCA

1.73

0.63–4.75

0.290

GDCA

0.98

0.23–4.11

0.975

TCA/CA

2.85

0.79–10.29

0.109

TCDCA/CDCA

0.45

0.17–1.22

0.116

GCA/CA

0.36

0.09–1.56

0.173

GCDCA/CDCA

2.2

0.83–5.86

0.113

TDCA/DCA

0.81

0.21–3.05

0.752

TLCA/LCA

0.4

0.12–1.38

0.149

GDCA/DCA

0.92

0.28–2.99

0.885

GLCA/LCA

0.76

0.32–1.82

0.537

GUDCA/UDCA

3.76

1.17–12.1

0.026

  1. HR  hazard ratio, CI  confidence interval, CA cholic acid, CDCA chenodeoxycholic acid, TCA taurocholic acid, TCDCA taurochenodeoxycholic acid, GCA glycocholic acid, GCDCA glycochenodeoxycholic acid, DCA deoxycholic acid, LCA lithocholic acid, UDCA ursodeoxycholic acid, TDCA taurodeoxycholic acid, TLCA taurolithocholic acid, GDCA glycodeoxycholic acid, GLCA glycolithocholic acid, GUDCA glycoursodeoxycholic acid